MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    DIFFERENCE IN MOTOR AND NONMOTOR SYMPTOMS BETWEEN YOUNG AND LATE ONSET PARKINSON`S DISEASE

    LH. Horvat, Z. Popovic, T. Gilman Kuric, I. Rajkovaca Latic, T. Mirosevic Zubonja, J. Kragujevic, S. Tomic ()

    Objective: To evaluate difference in prevalence of nonmotor symptoms and severity of autonomic and motor symptoms between patients with young (YOPD) and late onset (LOPD)…
  • 2022 International Congress

    Characterization of neuromelanin MRI as a potential Parkinson’s Disease biomarker in a multi-site longitudinal study

    M. Ingalhalikar, H. Pham, L. Bracoud, RM. Hutchison, K. Evans, T. Dam, M. Sampat, J. Schaerer, C. Conklin, J. Suhy, D. Scott (San Mateo, USA)

    Objective: To investigate (1)longitudinal change and (2)cross-sectional vendor differences in neuromelanin MRI in substantia nigra pars compacta(SNpc) in PD patients. Background: Neuromelanin(NM) MRI is a…
  • 2022 International Congress

    Outcome and mortality of hospital admission with COVID-19 in parkinsonian syndromes

    L. Sorrell, A. Barnett, A. King, J. Inches, J. Rideout, J. Sneyd, C. Kobylecki, K. Chaudhuri, R. Walker, H. Martin, K. Stevens, S. Campbell, C. Carroll (Plymouth, United Kingdom)

    Objective: To evaluate features associated with poor outcome and mortality of COVID-19 in people with Parkinson’s disease (PD) and atypical Parkinsonian syndromes (APS) in a…
  • 2022 International Congress

    Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD)

    E. Brown, D. Alonso, L. Chahine, C. Coffey, R. Dobkin, M. Korell, A. Lorenzo, C. Marras, W. Poewe, T. Sherer, A. Siderowf, T. Simuni, E. Tolosa, J. Valverde Twiggs, D. Weintraub, S. Chowdhury, K. Marek, C. Tanner (San Francisco, USA)

    Objective: To establish a large, longitudinal online cohort linked with a selected, intensively assessed cohort of people with and without PD to characterize development and…
  • 2022 International Congress

    Botulinum neurotoxin simulation workshop: Impact on resident satisfaction and knowledge

    C. Selvadurai, E. Cournean, N. Prakash, B. Rodrigues (Farmington, USA)

    Objective: To assess resident satisfaction and knowledge after a hands-on Botulinum toxin (BoNT) simulation workshop (SW). Background: Despite having an application for BoNT in almost…
  • 2022 International Congress

    Impact of Nonmotor Symptoms on The Quality of Life of Parkinson’s Disease Patients

    R. Nindela, O. Tambun, S. Marisdina, E. Bahar (Palembang, Indonesia)

    Objective: This study examined the effect of nonmotor symptoms on the quality of life (QoL) of Parkinson's disease (PD) patients. Background: Parkinson's disease has a…
  • 2022 International Congress

    Predictors of loss to follow-up three years after inclusion in a prospective longitudinal cohort study in people with early Parkinson’s disease

    C. Pauly, AM. Hanff, G. Aguayo, A. Rauschenberger, A. Leist, C. Mccrum, M. Zeegers, R. Krüger (Luxembourg, Luxembourg)

    Objective: To investigate potentially modifiable predictors of loss to follow up (LTFU) three years after inclusion in a nationwide mono-centric Parkinson’s cohort study. Background: LTFU…
  • 2022 International Congress

    FACIAL EMOTION EXPRESSIVITY IN PARKINSON’S AND ALZHEIMER’S DISEASES

    A. Cannavacciuolo, A. Guerra, D. Colella, M. Salzillo, A. de Biase, G. Paparella, M. Canevelli, G. Bruno, A. Berardelli, M. Bologna (Pozzilli, Italy)

    Objective: We here aimed to comprehensively investigate facial emotion expressivity in Parkinson’s disease (PD) and Alzheimer’s disease (AD) patients compared to healthy controls (HCs). Background:…
  • 2022 International Congress

    Nocturnal Polyuria in Parkinson’s Disease

    M. Smith, G. Portlock, A. Cullen, M. Drake, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

    Objective: To characterise the prevalence of nocturnal polyuria in a cohort of people with Parkinson’s disease (PD) with lower urinary tract symptoms. Background: Lower urinary…
  • 2022 International Congress

    Distinct Patterns of Tremor Network Microstructure for Essential Tremor and Parkinson’s Disease

    T. Welton, A. Ong, S. Hartono, Y-C. Shih, A. Lee, E-K. Tan, L-L. Chan (Singapore, Singapore)

    Objective: We aimed to identify differential patterns of aberrant tremor network microstructure using DSI among the following groups: (1) ET, (2) PD, and (3) healthy…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley